JP6422977B2 - 抗血清アルブミンｆａｂエフェクター部分融合コンストラクト、およびその製造方法 - Google Patents

抗血清アルブミンｆａｂエフェクター部分融合コンストラクト、およびその製造方法 Download PDF

Info

Publication number
JP6422977B2
JP6422977B2 JP2016538860A JP2016538860A JP6422977B2 JP 6422977 B2 JP6422977 B2 JP 6422977B2 JP 2016538860 A JP2016538860 A JP 2016538860A JP 2016538860 A JP2016538860 A JP 2016538860A JP 6422977 B2 JP6422977 B2 JP 6422977B2
Authority
JP
Japan
Prior art keywords
factor
protein
fab
peptide
hgh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016538860A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016528922A (ja
Inventor
チャ，サンフン
Original Assignee
エイプリルバイオ カンパニー リミテッド
エイプリルバイオ カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイプリルバイオ カンパニー リミテッド, エイプリルバイオ カンパニー リミテッド filed Critical エイプリルバイオ カンパニー リミテッド
Publication of JP2016528922A publication Critical patent/JP2016528922A/ja
Application granted granted Critical
Publication of JP6422977B2 publication Critical patent/JP6422977B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016538860A 2013-08-30 2014-08-29 抗血清アルブミンｆａｂエフェクター部分融合コンストラクト、およびその製造方法 Active JP6422977B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2013-0104112 2013-08-30
KR20130104112 2013-08-30
PCT/KR2014/008106 WO2015030539A1 (en) 2013-08-30 2014-08-29 An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018106308A Division JP6800180B2 (ja) 2013-08-30 2018-06-01 抗血清アルブミンｆａｂエフェクター部分融合コンストラクト、およびその製造方法

Publications (2)

Publication Number Publication Date
JP2016528922A JP2016528922A (ja) 2016-09-23
JP6422977B2 true JP6422977B2 (ja) 2018-11-14

Family

ID=52586989

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016538860A Active JP6422977B2 (ja) 2013-08-30 2014-08-29 抗血清アルブミンｆａｂエフェクター部分融合コンストラクト、およびその製造方法
JP2018106308A Active JP6800180B2 (ja) 2013-08-30 2018-06-01 抗血清アルブミンｆａｂエフェクター部分融合コンストラクト、およびその製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018106308A Active JP6800180B2 (ja) 2013-08-30 2018-06-01 抗血清アルブミンｆａｂエフェクター部分融合コンストラクト、およびその製造方法

Country Status (16)

Country Link
US (2) US9879077B2 (enExample)
EP (2) EP3632930A1 (enExample)
JP (2) JP6422977B2 (enExample)
KR (2) KR101576561B1 (enExample)
CN (1) CN105899532B (enExample)
AU (1) AU2014312456B2 (enExample)
BR (1) BR112016004355A2 (enExample)
CA (1) CA2922618C (enExample)
DK (1) DK3039038T3 (enExample)
ES (1) ES2866848T3 (enExample)
MX (1) MX371328B (enExample)
PH (1) PH12016500403A1 (enExample)
PL (1) PL3039038T3 (enExample)
RU (1) RU2661087C2 (enExample)
UA (1) UA117493C2 (enExample)
WO (1) WO2015030539A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108623691B (zh) * 2017-03-17 2020-05-15 北京比洋生物技术有限公司 IgG样长效免疫融合蛋白及其应用
CA3102036A1 (en) * 2018-06-18 2019-12-26 Anwita Biosciences, Inc. Cytokine fusion proteins and uses thereof
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
BR112022020256A2 (pt) 2020-04-09 2023-01-03 Aprilbio Co Ltd “anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
KR102485892B1 (ko) * 2020-04-09 2023-01-09 주식회사 에이프릴바이오 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
KR20220044057A (ko) * 2020-09-29 2022-04-06 주식회사 에이프릴바이오 인터루킨-18 결합 단백질 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질, 및 이의 용도
CN116262786B (zh) * 2021-12-13 2026-05-15 南京融捷康生物科技有限公司 针对folr1的单域抗体及其衍生蛋白和应用
KR20250024825A (ko) * 2022-06-15 2025-02-19 유씨비 바이오파마 에스알엘 폴리스타틴-fc 융합 단백질
KR20240048577A (ko) * 2022-10-04 2024-04-16 주식회사 에이프릴바이오 난포자극 호르몬 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
CN117327194A (zh) * 2023-09-01 2024-01-02 中国农业科学院生物技术研究所 细胞因子和铁蛋白亚基的融合蛋白及其制备方法和应用
WO2025253161A1 (en) * 2024-06-05 2025-12-11 Aprilbio Co., Ltd. Methods for treating liver diseases using recombinant fusion proteins comprising interleukin-18-binding protein and antigen binding fragment to serum albumin
CN118393137B (zh) * 2024-07-01 2024-08-20 广东赛尔生物科技有限公司 一种肠道保护菌的检测试剂盒及其应用
WO2026055874A1 (en) * 2024-09-12 2026-03-19 Quaerite Biopharm Research (Beijing) Co., Ltd. Formulations containing human serum albumin and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
CN1678634A (zh) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CN101031588A (zh) * 2004-06-01 2007-09-05 多曼蒂斯有限公司 药物组合物，融合物和结合物
US8921528B2 (en) * 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
KR20070041781A (ko) * 2004-08-11 2007-04-19 트루비온 파마슈티칼스, 인코포레이티드 결합 도메인 융합 단백질
CA2583137A1 (en) * 2004-10-05 2006-04-20 Genentech, Inc. Therapeutic agents with decreased toxicity
CA2589802A1 (en) * 2004-12-02 2006-06-08 Domantis Limited Plad domain peptides with increased serum half life due to conjugation to domain antibodies
EP1860120B1 (en) * 2005-02-08 2018-01-24 The Chemo-Sero-Therapeutic Research Institute Method for improving antibody
WO2008151319A2 (en) * 2007-06-08 2008-12-11 Dow Global Technologies Inc. Expression of soluble antibody fragment by truncation of ch1 domain
EP2535350B1 (en) * 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
JP5639039B2 (ja) * 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
US10407513B2 (en) * 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
CN102307897B (zh) * 2008-12-05 2016-01-20 葛兰素集团有限公司 选出蛋白酶抗性多肽的方法
WO2011015649A1 (en) * 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
GB201005063D0 (en) * 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
KR20120092611A (ko) * 2009-09-30 2012-08-21 글락소 그룹 리미티드 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트
JP6400470B2 (ja) * 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
JP6411214B2 (ja) * 2011-11-11 2018-10-24 ユーシービー バイオファルマ エスピーアールエル アルブミン結合抗体及びその結合断片

Also Published As

Publication number Publication date
PH12016500403A1 (en) 2016-05-16
RU2016105586A (ru) 2017-10-04
PL3039038T3 (pl) 2021-04-19
AU2014312456B2 (en) 2017-07-06
US20160376350A1 (en) 2016-12-29
MX371328B (es) 2020-01-27
RU2661087C2 (ru) 2018-07-11
KR20150118565A (ko) 2015-10-22
AU2014312456A8 (en) 2016-03-17
US9879077B2 (en) 2018-01-30
UA117493C2 (uk) 2018-08-10
EP3039038A4 (en) 2017-07-05
WO2015030539A1 (en) 2015-03-05
JP2016528922A (ja) 2016-09-23
JP2018172391A (ja) 2018-11-08
MX2016002539A (es) 2016-10-13
CA2922618C (en) 2020-04-28
US10618953B2 (en) 2020-04-14
KR101576561B1 (ko) 2015-12-10
HK1223107A1 (zh) 2017-07-21
EP3039038B1 (en) 2020-11-25
KR20150026997A (ko) 2015-03-11
EP3632930A1 (en) 2020-04-08
JP6800180B2 (ja) 2020-12-16
ES2866848T3 (es) 2021-10-19
US20180030127A1 (en) 2018-02-01
CA2922618A1 (en) 2015-03-05
CN105899532A (zh) 2016-08-24
DK3039038T3 (da) 2021-02-08
BR112016004355A2 (pt) 2017-10-17
CN105899532B (zh) 2021-10-08
EP3039038A1 (en) 2016-07-06
AU2014312456A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
JP6800180B2 (ja) 抗血清アルブミンｆａｂエフェクター部分融合コンストラクト、およびその製造方法
KR102271204B1 (ko) 다중특이적 항체 작제물
JP7727387B2 (ja) 新規の抗ｃｄ３９抗体
JP5087274B2 (ja) ポリペプチド
JP6498601B2 (ja) 多価ヘテロ多量体足場設計および構築物
US20240239889A1 (en) Anti-cd3-folate conjugates and their uses
JP2018093880A (ja) Ａｓｇｐｒ抗体およびその使用
JP2022081634A (ja) プロテアーゼで切断可能なリンカーを有するペプチド構築体
CA2589800A1 (en) Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
TW201742958A (zh) 功能性抗體片段的高通量篩選方法及其免疫偶聯物以及用於篩選之適體-藥物偶聯物
Kang et al. Optimal expression of a Fab-effector fusion protein in Escherichia coli by removing the cysteine residues responsible for an interchain disulfide bond of a Fab molecule
HK1223107B (en) An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof
HK1211302B (en) Asgpr antibodies and uses thereof
HK1205154A1 (en) Cx3cr1-binding polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170321

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170921

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180810

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180907

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180926

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181017

R150 Certificate of patent or registration of utility model

Ref document number: 6422977

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250